Clinical Trial Update: Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating bendamustine, rituximab, and acalabrutinib in Waldenström macroglobulinemia is currently active and not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• CALQUENCE (ACALABRUTINIB)
• Rituxan (rituximab)
• Treanda (Bendamustine)

Snippet

Sponsor: Sunnybrook Health Sciences Centre | Conditions: Waldenstrom Macroglobulinemia | Phase 2 | Status: ACTIVE_NOT_RECRUITING